Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, as defined by ADA criteria~* HbA1c \< 8% measured at least 1 month prior to this study~* BMI ≥27 kg/m2~* Pre-treatment with Metformin~* Age \> 18 and \< 65 years old~Exclusion Criteria:~* • Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza®~  * Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria~ * Insulin dependent or treated type 2 diabetes~ * Current use of other injectable incretins~ * History of diabetes ketoacidosis~ * Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) \< 30 mL/min/1.73m2~ * Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure~ * Clinical or laboratory evidences of chronic active liver diseases~ * Acute or chronic infective diseases~ * Cancer or chemotherapy~ * Current use of systemic corticosteroids or in the 3 months prior this study~ * Known or suspected allergy to Liraglutide, excipients, or related products~ * Pregnant, breast-feeding or the intention of becoming pregnant~ * Females of childbearing potential who are not using adequate contraceptive methods

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): • L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
- Metformin (Type: ACTIVE_COMPARATOR): M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl

Based on this trial design, predict the completion outcome and termination type (if applicable).